Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by jopatcloon Nov 22, 2024 3:38pm
44 Views
Post# 36326630

RE: First of a kind RCT for AI Echo Impl. in clinic.Us2.ai

RE: First of a kind RCT for AI Echo Impl. in clinic.Us2.ai
jopatclo wrote: Remember on website Ascend &
The BEST automation and analysis of the PLANET GEN3EHO &

The Future of Echo Reading is Here

Key Features

Gen3Echo combines the core capabilities of ASCEND CV Structured Reporting, InView DICOM Echo Viewer, flexible analytics, and AI integrations to provide a complete, seamless solution for echo interpretation.

Together, ASCEND’s portfolio of trusted products elevates echo reading and reporting workflow to a new level of productivity: 

Examples include:

  • Us2.ai - Benefit from the the industry’s most sophisticated integration of Us2.ai.
    • Us2.ai FDA-approved measurements feed ASE-validated suggested interpretations that can automatically complete the echo report 
    • Save time with single-click navigation to the automated measurement source frame 
    • 1-click sync to automated measurement frame
    • Distinct review processes for FDA-cleared versus investigational measurements, enhancing compliance and clarity 
    • Automatic grouping of Us2.ai measurements accelerates the measurement review process 
    • Visual notification of user edits performed on Us2.ai measurements promotes transparency and traceability 
  • Engineered for seamless integrationGen3Echo was designed with commitment to openness, seamlessly integrating with AI, ML, and advanced visualization software to foster innovation and collaboration. 
    • Ventripoint - The integration of Gen3Echo with Ventripoint’s innovative application of AI to echocardiography provides tremendous value to pediatric and adult echocardiographers in caring for their most complex patients

 https://ascendcv.com/
First of a kind RCT for AI Echo Implementation in clinical practice

The missing piece of the scientific evidence puzzle for AI Echo adoption

Follow Us2.ai as we unveil the results of the study presented at American Heart Association LBT 2024 !
 Top 5 game-changing benefits of adding Us2.ai to your clinical workflow

The AI-ECHO RCT, presented at AHA 2024 reveals the benefits of Us2.ai, AI-Echocardiography for your clinical workflow.

Follow along as we will share key insights from Nobuyuki Kagiyama on how AI can transform your clinical workflow and patient care.

Thinking about using Us2.ai in your clinical practice? Trust us—you won’t want to miss it!

Stay tuned to discover how Us2.ai can revolutionize your practice.

hashtagCardiology hashtagAIinHealthcare hashtagEchoInnovation hashtagAHA2024 hashtagAIEcho hashtagEcho hashtagEchocardiography hashtagPatientsFirst hashtagHeartHealth hashtagEchoFirst


 now 0.145 Mayo Clinic ok for Ventripoint V3.2 so good for me too with the V4.0 FDA coming... Attachez vos ceintures — nous nous dirigeons vers#PCRLondonValves! Angiopro GmbH .Good time to get in.3..... 2.... 1.... 0.... Launch! Dr. Adams is a visionary with Ventripoint I think they know more about the Ventripoint tech than the whiners on this board. Something could happen anytime real fast! FDA V4.0 and Sales (now Very good new VMS+ has been acquired by:Duke University Hospital,Mayo Clinic,Phoenix Children’s Hospital,Seattle Children’s Hospital) at any time now That V4.0 Europe & Canada OK & CardioLogic Ltd Introducing Ventripoint 4.0!


<< Previous
Bullboard Posts
Next >>